27494903|t|Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN - augmenting activity in airway epithelium
27494903|a|Exacerbations of asthma and COPD are triggered by rhinoviruses. Uncontrolled inflammatory pathways, pathogenic bacterial burden and impaired antiviral immunity are thought to be important factors in disease severity and duration. Macrolides including azithromycin are often used to treat the above diseases, but exhibit variable levels of efficacy. Inhaled corticosteroids are also readily used in treatment, but may lack specificity. Ideally, new treatment alternatives should suppress unwanted inflammation, but spare beneficial antiviral immunity. In the present study, we screened 225 novel macrolides and tested them for enhanced antiviral activity against rhinovirus, as well as anti-inflammatory activity and activity against Gram-positive and Gram-negative bacteria. Primary bronchial epithelial cells were grown from 10 asthmatic individuals and the effects of macrolides on rhinovirus replication were also examined. Another 30 structurally similar macrolides were also examined. The oleandomycin derivative Mac5, compared with azithromycin, showed superior induction (up to 5-fold, EC 50 = 5-11 μM) of rhinovirus - induced type I IFNβ, type III IFNλ1 and type III IFNλ2/3 mRNA and the IFN - stimulated genes viperin and MxA, yet had no effect on IL-6 and IL-8 mRNA. Mac5 also suppressed rhinovirus replication at 48 h, proving antiviral activity. Mac5 showed antibacterial activity against Gram-positive Streptococcus pneumoniae; however, it did not have any antibacterial properties compared with azithromycin when used against Gram-negative Escherichia coli (as a model organism) and also the respiratory pathogens Pseudomonas aeruginosa and non-typeable Haemophilus influenzae. Further non-toxic Mac5 derivatives were identified with various anti-inflammatory, antiviral and antibacterial activities. The data support the idea that macrolides have antiviral properties through a mechanism that is yet to be ascertained. We also provide evidence that macrolides can be developed with anti-inflammatory, antibacterial and antiviral activity and show surprising versatility depending on the clinical need.
27494903	0	14	Identification	T080	C0205396
27494903	18	23	novel	T080	C0205314
27494903	24	34	macrolides	T109,T121	C0282563
27494903	40	53	antibacterial	T039	C0544570
27494903	55	72	anti-inflammatory	T080	C1515999
27494903	77	83	type I	T116,T121,T129	C0021747
27494903	88	95	III IFN	T116,T121,T129	C0021747
27494903	98	117	augmenting activity	T033	C0243095
27494903	121	127	airway	T023	C0458827
27494903	128	138	epithelium	T024	C0014609
27494903	139	162	Exacerbations of asthma	T033	C0349790
27494903	167	171	COPD	T047	C0740304
27494903	176	188	triggered by	T080	C1444748
27494903	189	201	rhinoviruses	T005	C0035473
27494903	203	215	Uncontrolled	T080	C0205318
27494903	216	237	inflammatory pathways	T042	C1512758
27494903	239	249	pathogenic	T001	C0450254
27494903	250	259	bacterial	T080	C0521009
27494903	260	266	burden	T078	C2828008
27494903	271	279	impaired	T169	C0221099
27494903	280	298	antiviral immunity	T040	C1155328
27494903	327	334	factors	T169	C1521761
27494903	338	354	disease severity	T080	C0521117
27494903	359	367	duration	T079	C0872146
27494903	369	379	Macrolides	T109,T121	C0282563
27494903	390	402	azithromycin	T109,T195	C0052796
27494903	421	426	treat	T169	C1522326
27494903	437	445	diseases	T047	C0012634
27494903	451	458	exhibit	T080	C0443289
27494903	459	467	variable	T080	C0439828
27494903	468	474	levels	T080	C0441889
27494903	478	486	efficacy	T080	C1280519
27494903	488	511	Inhaled corticosteroids	T121	C4020618
27494903	537	546	treatment	T169	C1522326
27494903	556	560	lack	T080	C0332268
27494903	561	572	specificity	T081	C0037791
27494903	587	596	treatment	T169	C1522326
27494903	617	625	suppress	T169	C1260953
27494903	635	647	inflammation	T046	C0021368
27494903	670	688	antiviral immunity	T040	C1155328
27494903	705	710	study	T059	C0947630
27494903	728	733	novel	T080	C0205314
27494903	734	744	macrolides	T109,T121	C0282563
27494903	749	755	tested	T169	C0039593
27494903	765	773	enhanced	T052	C2349975
27494903	774	792	antiviral activity	T044	C1321382
27494903	801	811	rhinovirus	T005	C0035473
27494903	824	850	anti-inflammatory activity	T033	C0243095
27494903	855	863	activity	T052	C0441655
27494903	872	885	Gram-positive	T007	C0018154
27494903	890	912	Gram-negative bacteria	T007	C0018150
27494903	914	921	Primary	T080	C0205225
27494903	922	948	bronchial epithelial cells	T025	C1711178
27494903	968	989	asthmatic individuals	T101	C0030705
27494903	998	1005	effects	T080	C1280500
27494903	1009	1019	macrolides	T109,T121	C0282563
27494903	1023	1033	rhinovirus	T005	C0035473
27494903	1034	1045	replication	T043	C0042774
27494903	1056	1064	examined	T033	C0332128
27494903	1098	1108	macrolides	T109,T121	C0282563
27494903	1119	1127	examined	T033	C0332128
27494903	1133	1145	oleandomycin	T109,T195	C0028923
27494903	1146	1156	derivative	T169	C1527240
27494903	1157	1161	Mac5	T109,T195	C0028923
27494903	1177	1189	azithromycin	T109,T195	C0052796
27494903	1207	1216	induction	T169	C0205263
27494903	1232	1234	EC	UnknownType	C0678791
27494903	1252	1262	rhinovirus	T005	C0035473
27494903	1265	1272	induced	T169	C0205263
27494903	1273	1284	type I IFNβ	T028	C1334081
27494903	1286	1300	type III IFNλ1	T028	C1334085
27494903	1305	1321	type III IFNλ2/3	T028	C1334085
27494903	1322	1326	mRNA	T114,T123	C0035696
27494903	1335	1338	IFN	T116,T121,T129	C0021747
27494903	1341	1351	stimulated	T070	C1948023
27494903	1352	1357	genes	T028	C0017337
27494903	1358	1365	viperin	T028	C1539703
27494903	1370	1373	MxA	T028	C1417510
27494903	1383	1392	no effect	T080	C1301751
27494903	1396	1400	IL-6	T028	C1334122
27494903	1405	1409	IL-8	T028	C1366571
27494903	1410	1414	mRNA	T114,T123	C0035696
27494903	1416	1420	Mac5	T109,T195	C0028923
27494903	1426	1436	suppressed	T169	C1260953
27494903	1437	1447	rhinovirus	T005	C0035473
27494903	1448	1459	replication	T043	C0042774
27494903	1466	1467	h	T079	C0439227
27494903	1477	1495	antiviral activity	T044	C1321382
27494903	1497	1501	Mac5	T109,T195	C0028923
27494903	1509	1531	antibacterial activity	T039	C0544570
27494903	1540	1553	Gram-positive	T007	C0018154
27494903	1554	1578	Streptococcus pneumoniae	T007	C0038410
27494903	1609	1633	antibacterial properties	T039	C0544570
27494903	1634	1642	compared	T052	C1707455
27494903	1648	1660	azithromycin	T109,T195	C0052796
27494903	1679	1692	Gram-negative	T007	C0018150
27494903	1693	1709	Escherichia coli	T007	C0014834
27494903	1745	1766	respiratory pathogens	T001	C4267729
27494903	1767	1789	Pseudomonas aeruginosa	T007	C0033809
27494903	1807	1829	Haemophilus influenzae	T007	C0018483
27494903	1849	1853	Mac5	T109,T195	C0028923
27494903	1871	1881	identified	T080	C0205396
27494903	1895	1912	anti-inflammatory	T080	C1515999
27494903	1914	1923	antiviral	T044	C1321382
27494903	1928	1952	antibacterial activities	T039	C0544570
27494903	1958	1962	data	T078	C1511726
27494903	1985	1995	macrolides	T109,T121	C0282563
27494903	2001	2021	antiviral properties	T044	C1321382
27494903	2032	2041	mechanism	T169	C0441712
27494903	2089	2097	evidence	T078	C3887511
27494903	2103	2113	macrolides	T109,T121	C0282563
27494903	2136	2153	anti-inflammatory	T080	C1515999
27494903	2155	2168	antibacterial	T039	C0544570
27494903	2173	2191	antiviral activity	T044	C1321382
27494903	2241	2249	clinical	T080	C0205210
27494903	2250	2254	need	T080	C0027552